Similar Papers

Paper Title
Journal
Date
Author
Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)
Suzanne Lentzsch ...
Blood | VOL. 138
Suzanne Lentzsch, et. al.Suzanne Lentzsch ...
05 Nov 2021
Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study
Youn H Kim ...
Blood | VOL. 134
Youn H Kim, et. al.Youn H Kim ...
13 Nov 2019
Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial
Carlo Gambacorti-Passerini ... Andreas Hochhaus
Blood | VOL. 138
Carlo Gambacorti-Passerini, et. al.Carlo Gambacorti-Passerini ... Andreas Hochhaus
05 Nov 2021
Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial
...
Blood | VOL. 138
, et. al. ...
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Woyach JA, Burbano GP, Ruppert AS, etal. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
-
Blood | VOL. 145
--
30 Jan 2025
A novel therapy with a rational design for AML.
Maria L Amaya
Blood | VOL. 145
Maria L AmayaMaria L Amaya
30 Jan 2025
For how long has this problem been there?
Niccolò Bolli ... Matteo Claudio Da Vià
Blood | VOL. 145
Niccolò Bolli, et. al.Niccolò Bolli ... Matteo Claudio Da Vià
30 Jan 2025
Targeting CD47: many misses; hopeful for a hit.
Lindsay Wilde ... Margaret Kasner
Blood | VOL. 145
Lindsay Wilde, et. al.Lindsay Wilde ... Margaret Kasner
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.